



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

## BIB DATA SHEET

CONFIRMATION NO. 6097

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/590,406	10/04/2006	514	1634	33584-US-PCT
<b>RULE</b>				
<b>APPLICANTS</b> Iwan Beuvink, Biel-Benken, SWITZERLAND; Anne Boulay, Blotzheim, FRANCE; Heidi Lane, Biel-Benken, SWITZERLAND; Terence O'Reilly, Basel, SWITZERLAND; George Thomas, Wyoming, OH;				
<b>** CONTINUING DATA *****</b> This application is a 371 of PCT/EP05/01849 02/22/2005 which claims benefit of 60/546,856 02/23/2004				
<b>** FOREIGN APPLICATIONS *****</b>				
<b>** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **</b> 04/15/2008				
Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Verified and Acknowledged <u>/JAMES MARTINELLI/</u> Examiner's Signature	<input type="checkbox"/> Met after Allowance Initials	<b>STATE OR COUNTRY</b> SWITZERLAND	<b>SHEETS DRAWINGS</b> 0	<b>TOTAL CLAIMS</b> 10
				<b>INDEPENDENT CLAIMS</b> 3
<b>ADDRESS</b> NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080 UNITED STATES				
<b>TITLE</b> P53 Wild-Type as Biomarker for the Treatment with Mtor Inhibitors in Combination With a Cytotoxic Agent				
<b>FILING FEE RECEIVED</b> 1030	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	